Brief: Creative Medical Technology Holdings Announces IRB Approval For FDA Cleared Phase 1/2 Clinical Trial Of Stemspine® Using Allostem™ Novel Cell Therapy To Treat Chronic Lower Back Pain
10/10/2023 13:40
Oct 10 (Reuters) - Creative Medical Technology Holdings
Inc CELZ.O :
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES IRB
APPROVAL FOR
FDA CLEARED PHASE 1/2 CLINICAL TRIAL OF STEMSPINE® USING
ALLOSTEM™ ("CELZ-201-DDT") NOVEL CELL THERAPY TO TREAT CHRONIC
LOWER BACK PAIN
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS - APPROVAL ALLOWS CO
TO
PROCEED WITH RECRUITMENT OF PHASE 1 /2 RANDOMIZED, DOUBLE BLIND,
PLACEBO CLINICAL TRIAL
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC - STUDY TO ENROLL
30
INDIVIDUALS SUFFERING FROM CHRONIC LOWER BACK PAIN CAUSED BY
DEGENERATIVE DISC DISEASE
Source text for Eikon: ID:nPn9dbrmka
Further company coverage: CELZ.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM